Updates are available Correction dated 2021-11-20

Article History

Received: 2 June 2021

Revised: 15 September 2021

Accepted: 24 September 2021

First Online: 1 October 2021

Change Date: 20 November 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00415-021-10906-x

Declarations

:

: <b>J Río</b> has received speaking honoraria and personal compensation for participating on Advisory Boards from Almirall, Bayer-Schering Healthcare, Biogen-Idec, Genzyme, Merck- Serono, Novartis, Teva, and Sanofi-Aventis. A Rovira serves on scientific advisory boards for Novartis, Sanofi-Genzyme, SyntheticMR, Biogen and OLEA Medical, and has received speaker honoraria from Bayer, Sanofi-Genzyme, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche and Biogen. C Gasperini has received fee as speaker or advisory board by Merck, Bayer, Biogen, Novartis, Teva, Genzyme. M Tintore has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals. MT is co-editor of Multiple Sclerosis Journal- ETC. L Prosperini has received fee as speaker or advisory board by Merck, Bayer, Biogen, Novartis, Teva, Genzyme. S Otero-Romero has received speaking and consulting honoraria from Genzyme, Biogen-Idec, Novartis, Roche, Excemed and Merk; and research support from Novartis. M Comabella has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis. C Nos has received compensation as steering committee member of clinical trials from Hoffmann-La Roche, and funding for registration in scientific meetings from Novartis. A Vidal-Jordana receives support for contracts Juan Rodes (JR16/00024) from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain; and has received speaking honoraria and travel expenses from Novartis, Roche, Teva, Biogen and Sanofi-Genzyme. C Tur is currently being funded by a Junior Leader La Caixa Fellowship. The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/PI20/11760008. She has also received the 2021 Merck’s Award for the Investigation in Multiple Sclerosis (<i>Ayudas para la Investigación en Esclerosis Múltiple</i>, 2021), awarded by the Merck Foundation. In 2015, she received an ECTRIMS Post-doctoral Research Fellowship and has received funding from the UK MS Society. She has also received honoraria and support for traveling from Merck Serono, Sanofi, Roche, TEVA Pharmaceuticals, Novartis, Biogen, Bayer and Ismar Healthcare. G. Arrambide has received compensation for consulting services or participation in advisory boards from Sanofi and Merck; research support from Novartis; travel expenses for scientific meetings from Novartis, Roche, and ECTRIMS; and speaking honoraria from Stendhal, Sanofi, Merck. G. Arrambide is a member of the executive committee of the International Women in Multiple Sclerosis (iWiMS) network. A. Cobo-Calvo has received grant from Instituto de Salud Carlos III, Spain; JR19/00007. Breogán Rodríguez-Acevedo has received honoraria for consulting services from Wellspect. C Auger has received speaking honoraria from Novartis, Biogen and Stendhal. J Sastre-Garriga has received compensation for participating on Advisory Boards, speaking honoraria and travel expenses for scientific meetings, consulting services or research support from Celgene, Novartis, Biogen, Teva, Merck, Almirall, and Genzyme. X Montalban has received speaking honoraria and travel expenses for participation inscientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past with Actelion, Amirall, Bayer, Biogen, Celgene, Genzyme, Hoffmann-La Roche, Novartis, Oryzon Genomics, Sanofi-Genzyme, and Teva Pharmaceutical. L Midaglia, I Galán, J Castilló, and A Zabalza report no disclosures.

: The local ethical committee approved the study, and all patients provided their informed consent.